CJC-1295 W DAC 5MG

CJC-1295 W DAC (5 mg)

CJC-1295 W DAC is a synthetic analog of the neuroendocrine peptide growth hormone-releasing hormone (GHRH) and its receptor agonist, designed for research applications in preclinical settings. This compound has been extensively studied for its ability to stimulate pituitary growth hormone (GH) secretion, which may impact various physiological processes in animal models. The DAC modification (diacetylcysteamine) enhances stability and bioavailability, making it a valuable tool in pharmacology and endocrinology research.

Research Context

CJC-1295 W DAC is primarily utilized in animal studies to investigate the physiological and pharmacological effects of growth hormone-releasing activity. Its role in modulating GH secretion has led to applications in exploring age-related declines in growth hormone production, metabolic regulation, and potential therapeutic mechanisms for conditions linked to pituitary dysfunction. Due to its receptor specificity, it serves as a model compound for understanding GHRH/GH signaling pathways in vivo.

Research Overview

CJC-1295 W DAC is administered in preclinical research to induce controlled GH release, often in combination with other hormones such as GHRP-6 or GHRP-2. Studies have examined its effects on muscle mass, bone density, metabolic adaptations, and immune responses in various animal models. The DAC modification improves pharmacokinetic properties, reducing degradation in circulation and extending drug half-life. Research in this area contributes to the broader understanding of growth hormone regulation and potential compensatory mechanisms in aging and disease states.

Key Research Focus Areas

• Investigation of growth hormone secretion dynamics and pituitary responsiveness in aging animal models.
• Exploration of metabolic effects, including lipolysis, glucose homeostasis, and body composition changes.
• Assessment of muscle protein synthesis and atrophy prevention in experimental conditions.
• Evaluation of bone mineral density and fracture risk reduction through GH-mediated pathways.
• Study of immune modulation and stress responses in controlled experimental settings.

Important Safety and Compliance Note

CJC-1295 W DAC is intended solely for research purposes in approved scientific institutions. Administration must comply with all applicable regulations governing preclinical drug development, including proper handling, storage, and disposal procedures. Researchers are responsible for adhering to ethical guidelines and safety protocols specific to their institution. This compound is not intended for human or veterinary therapeutic use and should only be used in accordance with approved experimental designs.